Overview

Procalcitonin Protocol to Shorten the Antibiotic Therapy in Febrile Neutropenia

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
0
Participant gender:
All
Summary
In this study the investigators aim to test if a procalcitonin (PCT) - guided strategy allows to reduce the antibiotic use in patients with febrile neutropenia hospitalized in a Brazilian tertiary university hospital, causing no harm.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Federal University of Minas Gerais
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Criteria
Inclusion Criteria:

- age > 18 years

- febrile neutropenia

- to be under antibiotic therapy

- signed informed consent

Exclusion Criteria:

- patients under antibiotic therapy for more than 72 hours before inclusion

- patients post allogenic bone-marrow transplant (BMT)

- patients presenting one or more of the following conditions at the time of
randomization:

- severe mucositis

- all-trans retinoic acid (ATRA) syndrome

- disseminated intravascular coagulation

- hypotension (systolic blood pressure < 90 mmHg or need for vasopressor to
maintain blood pressure)

- respiratory failure (arterial oxygen pressure < 60 mmHg while breathing room air)
or need for mechanical ventilation

- severe renal failure requiring hemodialysis

- patients with suspected (positive galactomannan assay in peripheral blood, nodular
lesions with halo in the chest CT) or microbiologically confirmed fungal infection

- bacteremia due to S. aureus

- microbiologically confirmed carbapenem resistant P. aeruginosa or A. baumanii
infection

- microbiologically confirmed pneumonia due to P. aeruginosa, A. baumanii or
Stenotrophomonas maltophilla

- suspected or confirmed infection caused by atypical microorganisms (virus, parasites,
P. jiroveci). Patients with localized HSV infection (e.g., labial) will be accepted
for inclusion

- infections requiring prolonged therapies, such as endocarditis and cerebral abscess

- clearly focal bacterial infections